Ginseng root will receive country-of-origin labeling at the retail level under a final rule the Department of Agriculture published in the Jan. 15 Federal Register. Under the rule, effective March 16, USDA will make funding available to develop an automated review tracking system and conduct audits of the retail supply chain, the agency says in a Jan. 12 release. American Botanical Council Executive Director Mark Blumenthal said in an e-mail that COO labeling "addresses a serious problem in the American ginseng-producing community," since roots grown in Southeast Asia are often imported by the U.S. as fraudulent "Wisconsin-grown" ginseng. The USDA rule incorporates the aim of the Ginseng Harvest Labeling Act of 2007, introduced by Wisconsin's congressional delegation to protect growers in the state (1"The Tan Sheet" Aug. 13, 2007, p. 7)
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The FDA will use electronic health records to “get eyes” on drugs immediately after approval, Commissioner Martin Makary told the DIA 2025 Global Annual Meeting. He also wants to reduce development time with better communication and new approval pathways.
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
